Education
About Us
Working with TipRanks
Follow Us
Intervacc AB (DE:2E9)
:2E9
2E9 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.02 - €0.31
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€29.19M
Enterprise Value€54.31M
Total Cash (Recent Filing)kr29.03M
Total Debt (Recent Filing)kr590.00K
Price to Earnings (P/E)―
Beta1.77
Next Earnings
May 14, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding340,813,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)42.18
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
2E9 FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was €0.02 and its highest was €0.31 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is €29.19M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is May 14, 2025 which is in 18 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on Feb 13, 2025. The company reported -€0.019 earnings per share for the quarter, missing the consensus estimate of -€0.017 by -€0.001.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is -0.02.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -€0.019 in its last earnings report, missing expectations of -€0.017. Following the earnings report the stock price went up 66.667%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in DE:2E9
---
Company Description
Intervacc AB
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
---
Technical Analysis
Oncopeptides AB
―
Xbrane Biopharma AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―
---